Scinai Immunotherapeutics (SCNI) Return on Capital Employed (2020 - 2026)

Scinai Immunotherapeutics has reported Return on Capital Employed for 6 years, with the latest figure at 71.24% in Q1 2026.

• Quarterly Return on Capital Employed changed N/A year-over-year to 71.24% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 71.24% (changed N/A YoY) and the FY2025 annual result came in at 88.98%, down 2572.0% from the prior year.
• Return on Capital Employed improved to 71.24% in Q1 2026 per SCNI's latest filing, from 78.18% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 74.37% in Q3 2022 and troughed at 87.12% in Q3 2023.
• A 4-year average of 40.67% and a median of 56.62% in 2023 frame the typical range for Return on Capital Employed.
• The widest YoY moves for Return on Capital Employed: up 8636 bps in 2023, down 16148 bps in 2023.
• Over 4 years, Return on Capital Employed stood at 74.94% in 2022, then soared by 115 bps to 11.42% in 2023, then plunged by 784 bps to 78.18% in 2024, then gained by 9 bps to 71.24% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 71.24%, 78.18%, and 67.4% for Q1 2026, Q4 2024, and Q3 2024 respectively.